197 related articles for article (PubMed ID: 21879448)
1. Rationale for HDAC inhibitor therapy in autoimmunity and transplantation.
Hancock WW
Handb Exp Pharmacol; 2011; 206():103-23. PubMed ID: 21879448
[TBL] [Abstract][Full Text] [Related]
2. HDAC inhibitor therapy in autoimmunity and transplantation.
Hancock WW; Akimova T; Beier UH; Liu Y; Wang L
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i46-54. PubMed ID: 22460138
[TBL] [Abstract][Full Text] [Related]
3. Histone/protein deacetylases and T-cell immune responses.
Akimova T; Beier UH; Liu Y; Wang L; Hancock WW
Blood; 2012 Mar; 119(11):2443-51. PubMed ID: 22246031
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases.
Edwards AJ; Pender SL
Biochem Soc Trans; 2011 Aug; 39(4):1092-5. PubMed ID: 21787354
[TBL] [Abstract][Full Text] [Related]
5. Deacetylase inhibition promotes the generation and function of regulatory T cells.
Tao R; de Zoeten EF; Ozkaynak E; Chen C; Wang L; Porrett PM; Li B; Turka LA; Olson EN; Greene MI; Wells AD; Hancock WW
Nat Med; 2007 Nov; 13(11):1299-307. PubMed ID: 17922010
[TBL] [Abstract][Full Text] [Related]
6. FOXP3 ensembles in T-cell regulation.
Li B; Samanta A; Song X; Furuuchi K; Iacono KT; Kennedy S; Katsumata M; Saouaf SJ; Greene MI
Immunol Rev; 2006 Aug; 212():99-113. PubMed ID: 16903909
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
8. Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance.
Wang L; Tao R; Hancock WW
Immunol Cell Biol; 2009; 87(3):195-202. PubMed ID: 19172156
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells.
de Zoeten EF; Wang L; Butler K; Beier UH; Akimova T; Sai H; Bradner JE; Mazitschek R; Kozikowski AP; Matthias P; Hancock WW
Mol Cell Biol; 2011 May; 31(10):2066-78. PubMed ID: 21444725
[TBL] [Abstract][Full Text] [Related]
10. Isoform-specific histone deacetylase inhibitors: the next step?
Balasubramanian S; Verner E; Buggy JJ
Cancer Lett; 2009 Aug; 280(2):211-21. PubMed ID: 19289255
[TBL] [Abstract][Full Text] [Related]
11. Use of a cocktail regimen consisting of soluble galectin-1, rapamycin and histone deacetylase inhibitor may effectively prevent type 1 diabetes.
Jiang GX; Cui YF; Zhong XY; Tai S; Liu W; Wang ZD; Shi YG
Arch Med Res; 2009 Jul; 40(5):424-6. PubMed ID: 19766909
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms.
Beier UH; Wang L; Han R; Akimova T; Liu Y; Hancock WW
Sci Signal; 2012 Jun; 5(229):ra45. PubMed ID: 22715468
[TBL] [Abstract][Full Text] [Related]
13. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
14. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: molecular mechanisms of action.
Xu WS; Parmigiani RB; Marks PA
Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
[TBL] [Abstract][Full Text] [Related]
16. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs.
Akimova T; Ge G; Golovina T; Mikheeva T; Wang L; Riley JL; Hancock WW
Clin Immunol; 2010 Sep; 136(3):348-63. PubMed ID: 20478744
[TBL] [Abstract][Full Text] [Related]
17. HDACi--targets beyond chromatin.
Buchwald M; Krämer OH; Heinzel T
Cancer Lett; 2009 Aug; 280(2):160-7. PubMed ID: 19342155
[TBL] [Abstract][Full Text] [Related]
18. HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis.
Zhang ZY; Schluesener HJ
Prostate; 2012 Jan; 72(1):90-9. PubMed ID: 21538420
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo.
Faraco G; Pittelli M; Cavone L; Fossati S; Porcu M; Mascagni P; Fossati G; Moroni F; Chiarugi A
Neurobiol Dis; 2009 Nov; 36(2):269-79. PubMed ID: 19635561
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors in the treatment of lymphoma.
Lemoine M; Younes A
Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
